Case Presentation: Anesthetic Management For POEM Procedure in a Patient with Severe Pulmonary Hypertension CHUCK STRAUBHAAR BSN, SRNA

Similar documents
Nothing to Disclose. Severe Pulmonary Hypertension

Pulmonary Hypertension Perioperative Management

Pulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine

Pulmonary Hypertension in 2012

THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines

A Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis

PULMONARY HYPERTENSION & THALASSAEMIA

Recent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine

Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college

Pulmonary Hypertension: Clinical Features & Recent Advances

Pulmonary Arterial Hypertension: The Approach to Management in 2019

5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none

Pulmonary Hypertension: Evolution and

Pulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes

Cardiovascular Effects of Anesthesia for Cesarean Delivery in the Cardiac Patient

Pediatric Pulmonary Hypertension: Inside Out

Approach to Pulmonary Hypertension in the Hospital

ino in neonates with cardiac disorders

Patient Case. Patient Case 6/1/2013. Treatment of Pulmonary Hypertension in a Community

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)

Disclosures. ICU Management of Advanced Lung Disease 5/9/2015. No Disclosures. All pictures from commercial sources

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University

4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology

ADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION

PREOPERATIVE CARDIOPULMONARY ASSESSMENT FOR LIVER TRANSPLANTATION James Y. Findlay Mayo Clinic College of Medicine, Rochester, MN, USA.

Teaching Round Claudio Sartori

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin

CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION

Pulmonary Hypertension: Another Use for Viagra

Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ

Sotatercept PULSAR Phase 2 PAH Webinar. March 28, 2018

PULMONARY ARTERIAL HYPERTENSION AGENTS

Pulmonary hypertension on. Simon MacDonald BSc(Hons) BMBCh DPhil FRCP Consultant Cardiologist in Adult Congenital Heart Disease

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced

Disclosures. Objectives 6/16/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension

Pulmonary Arterial Hypertension - Overview

Pulmonary Arterial Hypertension - Overview

Disclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension

Pulmonary Vasodilator Treatments in the ICU Setting

Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH

Pulmonary Hypertension Due to Left Heart Disease

Hypotension after induction, corrected with 20 mg ephedrine x cc LR EBL 250cc Urine output:

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program

Conflicts of Interest

Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06

Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON

Anesthetic Techniques in Endoscopic Sinus and Skull Base Surgery

Pulmonary hypertension. Miloslav Špaček, MD

8/26/14. Disclosures. Objectives. None

See Important Reminder at the end of this policy for important regulatory and legal information.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

A Best Practices Approach to Treating Pulmonary Hypertension for the ED and Acute Care Provider. Disclosures

Pharmacy Management Drug Policy

More History. Organization. Maternal Cardiac Disease: a historical perspective. The Parturient with Cardiac Disease 9/21/2012

Oral Therapies for Pulmonary Arterial Hypertension

The Challenging Pediatric Cardiac Patient. Edmund Jooste

Children s of Alabama. Birmingham, Alabama

Index. Note: Page numbers of article titles are in boldface type.

Scleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas

Clinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88

Pulmonary Hypertension: Definition and Unmet Needs

buteykobreathing.co.nz Melanie Kalmanowicz, MD Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center

Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?

Therapeutic approaches in P(A)H and the new ESC Guidelines

Childhood Obesity: Anesthetic Implications

1

Neuro Quiz 25 - Monitoring

Frederic J., Gerges MD. Ghassan E. Kanazi MD., Sama, I. Jabbour-Khoury MD. Review article from Journal of clinical anesthesia 2006.

PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER

PRIMARY PULMONARY ARTERIAL HYPERTENSION AND PREGNANCY HOW PREPARED ARE WE?

Pulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH

DECLARATION OF CONFLICT OF INTEREST

The Case of Marco Nazzareno Galiè, M.D.

Managing Multiple Oral Medications

Pharmacologic Treatment of Neonatal Pulmonary Hypertension

Information Often Given to the Nurse at the Time of Admission to the Postanesthesia Care Unit

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Role of pulmonary vasodilators in the Fontan setting. Michael Cheung Melbourne

See Important Reminder at the end of this policy for important regulatory and legal information.

Cor pulmonale. Dr hamid reza javadi

final 1. Pulmonary Vascular Changes in Heart Disease. Normal Post-Natal Changes in the Pulmonary Circulation. Exercise. Pulmonary Circulation

Update on pulmonary HTN

22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment

Pulmonary hypertension

Acute And perioperative care of the burn-injured patient. Anesthesiology, V 122, No 2

Cardiothoracic Fellow Expectations Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center

Anesthesiology in advanced radical surgery. Bruno Carrara Ospedali Riuniti di Bergamo

Effectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH

Achalasia: Classic View

The Sildenafil Controversy

Diastolic Heart Failure Uri Elkayam, MD

Dr. J. R. Rawal 1 ; Dr. H. S. Joshi 2 ; Dr. B. H. Roy 3 ; Dr. R. V. Ainchwar 3 ; Dr. S. S. Sahoo 3 ; Dr. A. P. Rawal 4 ; Dr. R. A.

Perioperative management of a patient with left ventricular failure

AVOIDING THE CRASH 3: RELAX, OPTIMAL POST-AIRWAY MANAGEMENT AVOIDING THE CRASH: OPTIMIZE YOUR PRE, PERI, AND POST AIRWAY MANAGEMENT

ICU Management of Minimally Invasive Cardiac Surgery

Hemodynamic Changes in Obstetric Anesthesia. Sonia Vaida PANA, Hershey, April 2009

Chapter 25. General Anesthetics

Lecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)

4/21/2018. The Role of Cardiac Catheterization in Pediatric PVD. The Role(s) of Cath in PVD. Pre Cath Management. Catheterization Mechanics in PVD

Update in Pulmonary Arterial Hypertension

Transcription:

Case Presentation: Anesthetic Management For POEM Procedure in a Patient with Severe Pulmonary Hypertension CHUCK STRAUBHAAR BSN, SRNA

OBJECTIVES Comprehend basic pathophysiology of pulmonary hypertension Appreciate anesthetic considerations and intraoperative management of pulmonary hypertension Understand anesthetic management and basic surgical technique for peroral endoscopic myotomy

PULMONARY VASCULATURE PHYSIOLOGY Low pressure system, less than 10% resistance to flow compared to systemic vasculature Normal pulmonary artery pressure at rest at sea level: 20/10 mm Hg Resting PA pressure rises with higher altitudes Systolic PA pressures gradually rise with age

PULMONARY HYPERTENSION PATHOPHYSIOLOGY Pulmonary HTN: mean PA pressure greater 25 mm Hg Pulmonary arterial hypertension: left sided heart filling pressure must be 15 mm Hg or less 5 clinical classifications PA pressures and PVR increased at rest RV hypertrophy impaired LV filling impaired CO progressive RV failure and sudden death

PULMONARY ARTERIAL HYPERTENSION PATHOBIOLOGY Characterized by endothelial dysfunction, apoptosis:proliferation in pulmonary arterial smooth muscle, thickened adventitia Panvasculopathy affecting small pulmonary arterioles Intimal hyperplasia, medial hypertrophy, adventitial proliferation Imbalance of vasoactive mediators Not enough nitric oxide and prostacyclin Too much thromboxane and endothelin

PULMONARY HYPERTENSION ANESTHETIC CONSIDERATIONS Preanesthesia evaluation and preoperative testing Intraoperative goals Avoid increased pulmonary vascular resistance Maintain preload but avoid fluid overload Maximize RV O2 supply, minimize O2 demand MAC/peripheral nerve block vs Neuraxial vs General Laparoscopic vs open procedures Standard monitoring +/- arterial line, CVC, PAC, TEE

PULMONARY HYPERTENSION ANESTHETIC CONSIDERATIONS Induction slow and steady Short acting hypnotic (etomidate 0.15-0.3 mg/kg), moderate dose of opioid (fentanyl 1-2 mcg/kg), lidocaine 50-100 mg, muscle relaxant Critical to maintain oxygenation and avoid hypercarbia Maintenance avoid increased PVR and decreased SVR Minimal data on inhalational anesthetic effects on PVR Best to avoid nitrous oxide and ketamine TIVA? Ventilation avoid high peak pressures/high PEEP, acidosis, hypoxia, and atelectasis Fluid avoid abrupt changes Emergence smooth

PULMONARY HYPERTENSION ANESTHETIC CONSIDERATIONS

PULMONARY HYPERTENSION TREATMENT For groups 2-5, management of the underlying disease process Group 1 Pulmonary Arterial Hypertension Prostacyclin agonists (epoprostenol, treprostinil) Endothelin receptor antagonist (bosentan, ambrisentan) Nitric oxide-cgmp enhancers (sildenafil, tadalafil)

PERORAL ENDOSCOPIC MYOTOMY (POEM)

POEM PROCEDURE AND ANESTHESIA CONSIDERATIONS Indicated for achalasia esophageal dysmotility Clear liquids only 1-5 days preop, and NPO at least 6 hours preop May still retain contents in esophagus Performed in OR or high-intensity endoscopy suite Reverse trendelenburg and RSI recommended Supine throughout procedure, EBL minimal, 1 PIV Stimulating? Adverse events: insufflation-related, bleeding, mucosal perforation

No general anesthesia if possible. If no alternative to GA, she will need anesthesia with knowledge of how to manage PH and RV failure, as risk of decompensation following intubation is HIGH Perioperative cardiopulmonary risk is high CASE PRESENTATION

KC is a 29 year old female, 170 cm, 59 kg presenting for a POEM procedure due to gastroparesis, persistent N/V, and early satiety. Other history: severe idiopathic pulmonary arterial HTN, right HF, mild asthma, 2 L O2 at night, and recent URI. KC is also being considered for a lung transplant, but can walk >1000 ft so not yet a candidate. KC has some atelectasis and diminished basilar breath sounds. Medications PAH: IV treprostinil via Hickman catheter, ambrisentan, riociguat Right HF: Lasix Asthma: Flonase, albuterol ECG: NSR, RAD, incomplete RBBB, nonspecific ST & T wave changes, QTc 551 ms CXR: cardiac silhouette enlarged. Main & central PAs dilated with abrupt peripheral tapering Rt heart cath: RV pressure 116/22, PA 116/60 (79) Echo: RV & RA severely dilated, RV function severely decreased, 1+ TR, 2+ PR. Main PA dilated at 6.1 cm

SO. WHAT DID WE DO? Pre-operative: continued PO PAH meds along with IV treprostinil, thorough interview Intra-operative: GETA with modified rapid sequence induction Alfentanil, etomidate, rocuronium Increasing peak pressures asthma/spasm? Rhonchi? Postoperative: PONV but prolonged QT What if things went wrong? Acute right heart failure inhaled nitric oxide or epoprostenol, IV milrinone Hypotension norepinephrine

Overall, there are many different ways anesthesia could have been provided to this patient. This way is not better or worse than other ways, but it did provide a safe anesthetic.

SOURCES Hopkins, W., & Rubin, L. J. (2018). Treatment of pulmonary hypertension in adults (J. Mandel & G. Finlay, Eds.). Retrieved August 4, 2018, from https://www.uptodate.com/contents/treatment-of-pulmonary-hypertension-inadults?sectionname=prostacyclin pathway agonists&topicref=94362&anchor=h21&source=see_link#h3257161491 Mclaughlin, V. (2016). Chapter 68 Pulmonary Hypertension. In Goldman Cecil Medicine (25th ed., pp. 397-403). Philadelphia, PA: Elsevier Saunders. Pannala, R., Abu Dayyeh, B. K., Aslanian, H. R., Enestvedt, B. K., Komanduri, S., Manfredi, M.,... Banerjee, S. (2016). Per-oral endoscopic myotomy. In Gastrointestinal Endoscopy(Vol. 83, pp. 1051-1060). Elsevier. Sharp, C. D., T. E., & Ginsberg, G. G. (2017). Anesthesia for Routine and Advanced Upper Gastrointestinal Endoscopic Procedures. In Anesthesiology Clinics (Vol. 35, pp. 669-674). Zafirova, Z., & Rubin, L. J. (2018). Anesthesia for patients with pulmonary hypertension or right heart failure (B. A. Borlaug, R. Hines, N. A. Nussmeier, & S. B. Yeon, Eds.). Retrieved August 4, 2018, from https://www.uptodate.com/contents/anesthesia-for-patients-with-pulmonary-hypertension-or-right-heartfailure?search=pulmonary%20hypertension%20anesthesia&source=search_result&selectedtitle=1~150&usage_t ype=default&display_rank=1#h1900480851

QUESTIONS?